Stoke Therapeutics Presents Data Related to the Ongoing Clin

– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac...

Related Keywords

United Kingdom , Cambridge , Cambridgeshire , Bedford , Massachusetts , United States , Ireland , Dublin , Helen Cross , Eric Rojas , Elaine Wirrell , Im Scott Perry , Exchange Commission , International League Against Epilepsy , Augmentation Of Nuclear Gene Output Is Stoke , John Justin Neurosciences Center , Nasdaq , Cook Children Medical Center , Stoke Therapeutics Inc , Company Annual Report On Form , International Epilepsy Congress , University College London Institute Of Child Health , Neurology Residency Training Program At Mayo Clinic , Augmentation Of Nuclear Gene Output , Stoke Therapeutics , Childhood Epilepsy , Child Health , Honorary Consultant , Paediatric Neurology , Dravet Syndrome , Senior Vice President , Clinical Pharmacology , Digital Poster Presentation , Ongoing Open Label , United Kingdom Investigating Safety , Drug Exposure , Antisense Oligonucleotide , Developmental Neuroscience Programme , International League Against , Previously Participated , Genetic Epilepsy Clinic , Cook Children , Investigate Cognition , Pediatric Epilepsy , Mayo Clinic , Adolescent Neurology Residency Training Program , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act , Annual Report , Investor Contacts , Investor Relations ,